Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in the multiple-ascending dose (MAD)...

K36 Therapeutics Named “Overall BioPharma Startup of the Year” By BioTech Breakthrough CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- K36 Therapeutics (“K36”) has been selected as “Overall BioPharma Startup of the Year” in the third annual BioTech Breakthrough Awards Program...

Hemispherx's Ampligen(R) Provides Anti-Tumor Activity Analogous to Emerging Immune Checkpoint Inhibitors PHILADELPHIA, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced today further progress on developing Ampligen® (rintatolimod)...

MolecularMD Corp. Obtains Exclusive License to LKB1 Uses in Non-Small Cell Lung Cancer PORTLAND, OR--(Marketwire - Jan 28, 2013) - MolecularMD Corp. announced today that it has entered into a license agreement granting the company exclusive patent rights to cancer diagnosis...